Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence

Detalles Bibliográficos
Autores principales: Abbasi, Haleema Qayyum, Maryyum, Adeena, Khan, Abdul Moiz, Shahnoor, Syeda, Oduoye, Malik O., Wechuli, Polyne N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389599/
https://www.ncbi.nlm.nih.gov/pubmed/37485921
http://dx.doi.org/10.1097/JS9.0000000000000334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389599/
https://www.ncbi.nlm.nih.gov/pubmed/37485921
http://dx.doi.org/10.1097/JS9.0000000000000334

Ejemplares similares